Gadolinium-based contrast agents and nephrogenic systemic fibrosis

Radiology

Volumn 250, Issue 3, 2009, Pages 959-

  Vitti, Richard A ^a  

^a GE HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADODIAMIDE;

CONTRAST ENHANCEMENT; CONTRAST INDUCED NEPHROPATHY; DOSE RESPONSE; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LETTER; NEPHROGENIC SYSTEMIC FIBROSIS; PRIORITY JOURNAL;

ACADEMIC MEDICAL CENTERS; ADOLESCENT; ADULT; AGED; CHELATING AGENTS; COMORBIDITY; GADOLINIUM; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; RENAL INSUFFICIENCY; RISK ASSESSMENT; RISK FACTORS; SCLERODERMA, SYSTEMIC; SYNDROME; UNITED STATES;

EID: 78650759752     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2503081497     Document Type: Letter

References (2)

1. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008;248(3):799- 806.
2. American College of Radiology. Manual on contrast media: version 6-2008 [book online]. Reston, Va: American College of Radiology, 2008. http://www.acr.org/SecondaryMainMenuCategories/quality-safety/contrast-manual. aspx. Updated October 6, 2008. Accessed December 10, 2008.